Treatments

*April 2021* During the past decade, evidence has been building that non–small cell lung cancer (NSCLC) has a distinct clinical and genomic profile in patients 40 years and younger. Now investigators have launched the Epidemiology of Young Lung Cancer (EoYLC) study (NCT04640259) to identify risk factors that can help shed…

*April 2021* Single-agent telisotuzumab vedotin (teliso-v; ABBV-399) induced an encouraging objective response rate (ORR) with a tolerable safety profile in patients with previously treated non–small cell lung cancer (NSCLC) who were c-MET positive, according to data from a phase 2 study (NCT03539536) presented in a virtual poster during the AACR…

*April 2021* NOTE: In a small percentage of EGFR+ lung cancer patients, transformation to SCLC can occur, perhaps as a resistance mechanism. Oncologists tend to treat SCLC transformation the same as de novo SCLC, but sometimes osimertinib is continued along with SCLC treatment. This article refers to de novo SCLC treatments, not…

*April 2021* The HER3-directed antibody-drug conjugate patritumab deruxtecan is under exploration in the treatment of patients with EGFR-mutated, metastatic or locally advanced non–small cell lung cancer who had previously received a TKI and platinum-based chemotherapy. Read more.

*March 2021* Jason Porter, MD, discusses potential sequencing strategies with antibody-drug conjugates and TKIs in HER2-positive lung cancer. Listen here.

*May 2021* The advent of molecular targeted therapies and the more recent introduction of immune checkpoint inhibitors (ICIs) have altered and improved the therapeutic landscape of non-small cell lung cancer (NSCLC). ICIs confer a durable response in a subset of patients; however, their therapeutic role in oncogene-driven NSCLC remains unclear,…

*March 2021* In this podcast, Benjamin P. Levy, MD, an associate professor of oncology and clinical director of Medical Oncology at Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, discusses exciting research with targeted therapies for patients with lung cancer who harbor molecular abberations. Dr. Levy discusses recent…

*March 2021* Osimertinib (Tagrisso) has demonstrated significant benefit in the frontline metastatic and adjuvant settings in patients with stage IV and stage IB-IIIA EGFR-mutant non–small cell lung cancer (NSCLC), respectively, explained Lara A. Kujtan, MD, but added that the ongoing phase 3 FLAURA2 (NCT04035486), LAURA (NCT03521154), and NeoADAURA (NCT04351555) trials could…

*April 2021* Lung cancer expert Dr. Pasi Janne, a professor of medicine at Harvard Medical School and a translational thoracic medical oncologist at the Dana-Farber Cancer Institute, speaks about EGFR treatments including post-progression following osimertinib. This is a very informative podcast and easy to understand. Listen to the podcast or read the…

*March 2021* Want to know more details about our two self-funded EGFR Resisters research projects in partnership with LUNGevity? 1. TARGETING DRUG TOLERANT STATES + DNA DAMAGE TO BLOCK OSIMERTINIB RESISTANCE, conducted by Christine Lovly, MD, PhD Despite high tumor response rates, patients treated with EGFR targeted therapies, such as osimertinib, inevitably…